Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Related Citations for PubMed (Select 19630865)

1.

Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy.

Jorquera JI.

Clin Exp Immunol. 2009 Sep;157 Suppl 1:17-21. doi: 10.1111/j.1365-2249.2009.03953.x. Erratum in: Clin Exp Immunol. 2009 Sep;157(3):446.

2.

Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.

Caballero S, Nieto S, Gajardo R, Jorquera JI.

Biologicals. 2010 Jul;38(4):486-93. doi: 10.1016/j.biologicals.2010.02.008. Epub 2010 Mar 29.

PMID:
20350815
3.

Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.

Ballow M.

Clin Exp Immunol. 2009 Sep;157 Suppl 1:22-5. doi: 10.1111/j.1365-2249.2009.03951.x. Erratum in: Clin Exp Immunol. 2009 Sep;157(3):446.

4.

Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.

Troccoli NM, McIver J, Losikoff A, Poiley J.

Biologicals. 1998 Dec;26(4):321-9.

PMID:
10403036
5.

Nanofiltration of plasma-derived biopharmaceutical products.

Burnouf T, Radosevich M.

Haemophilia. 2003 Jan;9(1):24-37. Review.

PMID:
12558776
6.

A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.

Poelsler G, Berting A, Kindermann J, Spruth M, Hämmerle T, Teschner W, Schwarz HP, Kreil TR.

Vox Sang. 2008 Apr;94(3):184-92. doi: 10.1111/j.1423-0410.2007.01016.x. Epub 2007 Dec 19.

PMID:
18167162
7.
8.

Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities.

José M, Marzo N, Pons B, Herrerias A, López L, Faro M, López M, Jorquera JI.

Biologicals. 2013 Nov;41(6):393-9. doi: 10.1016/j.biologicals.2013.08.002. Epub 2013 Sep 17.

PMID:
24051302
9.

Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.

Aghaie A, Pourfatollah AA, Bathaie SZ, Moazzeni SM, Khorsand Mohammad Pour H, Sharifi Z.

Hum Antibodies. 2008;17(3-4):79-84.

PMID:
19029665
10.

Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.

Roberts PL, Dunkerley C, Walker C.

Biologicals. 2012 Sep;40(5):345-52. doi: 10.1016/j.biologicals.2012.04.007. Epub 2012 May 30.

PMID:
22658506
12.

Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.

Soluk L, Price H, Sinclair C, Atalla-Mikhail D, Genereux M.

Am J Ther. 2008 Sep-Oct;15(5):435-43. doi: 10.1097/MJT.0b013e318160c1b7. Review.

PMID:
18806519
13.

Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency.

Berger M, Pinciaro PJ, Althaus A, Ballow M, Chouksey A, Moy J, Ochs H, Stein M.

J Clin Immunol. 2010 Mar;30(2):321-9. doi: 10.1007/s10875-009-9348-y. Epub 2009 Dec 8.

PMID:
19997861
14.

Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.

Chang CE, Eo HG, Lee YS, Chung SK, Shin JS, Lah YK, Park CW, Jung JT, Huh JW, Lee SM.

Prep Biochem Biotechnol. 2000 Aug;30(3):177-97. Erratum in: Prep Biochem Biotechnol 2001 Feb;31(1):81-2.

PMID:
10919559
15.

Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent.

Diez JM, Caballero S, Belda F, Otegui M, Gajardo R, Jorquera JI.

Biologicals. 2010 Nov;38(6):670-4. doi: 10.1016/j.biologicals.2010.08.003. Epub 2010 Sep 22.

PMID:
20863716
16.

Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.

Terpstra FG, Parkkinen J, Tölö H, Koenderman AH, Ter Hart HG, von Bonsdorff L, Törmä E, van Engelenburg FA.

Vox Sang. 2006 Jan;90(1):21-32.

PMID:
16359352
18.

Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations.

Yunoki M, Urayama T, Tsujikawa M, Sasaki Y, Abe S, Takechi K, Ikuta K.

Br J Haematol. 2005 Feb;128(3):401-4.

PMID:
15667545
19.

Physico-chemical and biological properties of solvent/detergent treated immunoglobuin G preparations.

Nesterova NV, Kurkina OV, Samoilenko VA, Skrynnyk MM.

Mikrobiol Z. 2009 Nov-Dec;71(6):35-42.

PMID:
20455431
20.

Inactivation and clearance of viruses during the manufacture of high purity factor IX.

Johnston A, Macgregor A, Borovec S, Hattarki M, Stuckly K, Anderson D, Goss NH, Oates A, Uren E.

Biologicals. 2000 Sep;28(3):129-36.

PMID:
10964439
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk